Root-cause treatment: therapy as the inverse substrate operation
Root-cause therapy is the inverse substrate operation. Five inverse ops — restore loop gain, raise the attractor barrier, re-engage the error signal, repair the instrument, lower a run-away loop gain — map onto seven diseases. Restoring loop gain re-deepens a collapsed basin (barrier 0.091 → 0.442, 73% recovered). Contested and partial results are flagged honestly.
If disease is a substrate operation (barrier collapse, off-criticality, aggregation crossing), then root-cause therapy is its inverse, and the restoration demo shows a treated barrier recovering from 0.091 back to 0.442 (73% of the healthy 0.571). Each disease is matched to one of five inverse operations with its clinical evidence level. The substrate mapping is [V-structure]; clinical efficacy is cited [L] — AMD complement inhibitors show no functional acuity gain yet, cataract chaperone reversal failed replication, and ATOH1-regenerated hair cells remain immature.
If the disease law is right that pathology is a substrate operation, then therapy that lasts must run that operation backwards. The restoration demo shows the principle quantitatively: restoring loop gain re-deepens a collapsed basin from 0.091 back to 0.442, recovering 73% of the healthy depth 0.571.
Five inverse operations
Each pathology mode has a matching inverse, and the seven diseases distribute across these five:
- (1) restore loop gain — re-deepen a collapsed basin (e.g. glycemic control in diabetic retinopathy).
- (2) raise the attractor barrier — protect the at-risk cells directly (RGC neuroprotection in glaucoma).
- (3) re-engage the error signal — turn a broken feedback loop back on (defocus / dopamine arm in myopia).
- (4) repair the instrument — regenerate or replace the failed part (hair cell, lens, or reposition otoconia).
- (5) lower a run-away loop gain — damp a positive-feedback loop (complement inhibition in AMD).
Seven diseases matched to their inverse operation
| disease | inverse op | root-cause therapy | evidence |
|---|---|---|---|
| glaucoma | (1)+(2) | ROCK inhibitors (netarsudil, ripasudil): restore TM outflow + RGC neuroprotection | approved (outflow); neuroprotection preclinical |
| myopia | (3) | re-engage defocus / dopamine arm: low-dose atropine, defocus optics, outdoor light, 650 nm red light | RCT-supported ≥50% slowing; IMI 2025 |
| presbycusis / SNHL | (4)+(1) | regenerate transducer + push µ back to criticality; repair IHC-SGN synapse; OTOF gene therapy | OTOF restored hearing in children (2024); ATOH1 cells immature |
| AMD (geographic atrophy) | (5) | complement inhibitors (pegcetacoplan C3, avacincaptad C5): lower the run-away loop gain | approved 2023 (anatomic); NO functional acuity gain yet |
| cataract | (1)/(4) | pharmacological chaperones / aggregation reversal (oxysterols); else lens replacement | CONTESTED: reversal failed replication (Daszynski 2019) |
| diabetic retinopathy | (1) | reset the systemic metabolic setpoint (glycemic control); anti-VEGF blocks the downstream attractor | glycemia root-causal; anti-VEGF for the complication |
| BPPV / vertigo | (4) | canalith repositioning (Epley / Semont): return otoconia at the source | established standard of care |
Root versus symptomatic
The contrast is sharp throughout: hearing aids substitute for the transducer rather than regrow it, single-vision glasses correct focus while the growth loop runs on, and anti-VEGF treats neovascular leakage downstream of the complement driver. Root-cause therapy targets the substrate operation itself — which is what makes a cure, rather than a management, conceivable.